Atlas Trials

Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

Clinical trial NCT06727227 · RECRUITING

Trial details

NCT number
NCT06727227
Sponsor
AstraZeneca
Status
RECRUITING
Study type
OBSERVATIONAL
Breast Cancer
Start date
2025-01-29
Primary completion
2027-10-31
Enrollment
138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.